From our October 2019 Newsletter

The WHO Global Tuberculosis Report 2019 is Out

The WHO 2019 Global Tuberculosis Report has recently been published. It was found that the global MDR-TB epidemic increased by approximately half a million new cases of rifampin-resistant TB (of which 78% had multidrug-resistant TB) in 2018. Check out the link to the full global TB report 2019 below, and other recent news in DR-TB.
1. Global Tuberculosis Report 2019
2. Global campaign launched urging Johnson & Johnson to reduce price of bedaquiline
3. TB drug delamanid must be more affordable and made available in more countries
4. DR-TB Drugs Under the Microscope, 6th edition

From our September 2019 Newsletter

News

Below is the most recent State of the Art article from IJTLD, which discusses the use of palliative care and symptom relief (PCSR) for people affected by MDR-TB.
1. Palliative care and symptom relief for people affected by multi-drug resistant tuberculosis
Below is the new 2019 Lancet tuberculosis series presenting how the diagnosis of MDR-TB can be improved, how drug regimens can best be used to treat and applied to different populations, and how MDR-TB can be managed in the future.
2. The Lancet Tuberculosis 2019

FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs

FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs

Posted on 08/15/19

The FDA has approved a new drug for highly-resistant forms of drug-resistant tuberculosis. Developed by the non-profit TB alliance, Pretomanid has been approved to be used in a combination regimen with bedaquiline and linezolid for people with MDR-TB and XDR-TB.

From our August 2019 Newsletter

News

Here are a few items that address the exciting news about the FDA approval of pretomanid in the BPaL regimen; describe concern about the standard of the research that led to its approval, the regulatory precedent it sets; and highlight uncertainty around its affordability and access.

1. FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs
2. New tuberculosis medicine studied in South Africa approved in United States
3. New Drug Could Be Game Changer For Drug-Resistant TB. But A Question Looms

From Our July 2019 Newsletter

News

1. NIH launches large TB prevention trial for people exposed to multidrug-resistant TB
A large clinical trial is being conducted to assess the treatments available for individuals who are at high-risk for developing multi-drug resistant tuberculosis (MDR-TB).

2. Management of patients with multidrug-resistant tuberculosis
Recommendations for the management of MDR-TB are discussed in this June issue of the State of the Art articles from IJTLD.